Katie Hand

• Alkermes plc in the spin-off of its oncology business into Mural Oncology plc
• Bluebird bio, Inc. in the spin-off of its oncology programs and portfolio into 2seventy bio, Inc.
• 2seventy bio, Inc. in its $170 million PIPE financing and its $125 million public offering
• Akero Therapeutics, Inc. in its initial public offering, multiple follow-on offerings of more than $425 million, a $25 million equity investment by Pfizer, Inc., its $100 million term loan facility with Hercules Capital, Inc. and day-to-day governance and reporting matters
• Tango Therapeutics, Inc. in connection with its $60 million Series B financing, its $1.0 billion definitive business combination with BCTG Acquisition Corp and its $80 million PIPE financing
• Clarus Therapeutics in connection with its definitive business combination 
• Avadel Pharmaceuticals plc in its $65 million financing transaction, $125 million follow-on offering and $125 million follow-on offering

• Lila Sciences, Inc. in its $350 million Series A financing
• ElevateBio, LLC in connection with its $193 million Series B financing, $525 million Series C financing, its $401 million Series D financing and the formation of its portfolio companies
• Openly in its $100 million Series D financing and other preferred stock financings
• Imagen Technologies, Inc. in its preferred stock financings 
• Firefly Health, Inc. in its preferred stock financings
• Versanis Bio, Inc. in its $113 million Series B financing and other preferred stock financings
• Vizit Labs, Inc. it its preferred stock financings 
• Zus Health, Inc. in its $34M Series A financing and other preferred stock financings

• Versanis Bio, Inc. in its merger with Eli Lilly and Company
• Fincura, in its sale to Numerated
• Mavrck, in its combination with Later

Katie has provided associate support for shareholder activism matters including for Anika Therapeutics, Cedar Realty Trust, Virtusa and Leaf Group in their defenses against activist campaigns.